You are here:

Archived: Memantine (Ebixa®)


Not recommended for use within NHS Scotland.


Although this is currently the only agent licensed for use in moderately severe to severe Alzheimer's disease, the magnitude of the effect is extremely small. Compared with placebo it is associated with a statistically significant reduction in the rate of deterioration in global, functional and cognitive scales. On the evidence presented, the associated gains appear to be marginal relative to the overall costs.

The license holder has indicated their decision to resubmit.

Drug Details

Drug Name: Memantine (Ebixa®)
SMC Drug ID: 57/03
Manufacturer: Lundbeck Ltd
Indication: Moderately severe to severe Alzheimer's disease
BNF Category:
Sub Category: 4.11 Drugs for dementia
Submission Type: Full submission
Status: Superseded
Date Advice Published: 11 August 2003

Current Advice

Resubmission 12 January 2004